English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 332 Help

Selected(0)Clear Items/Page:    Sort:
Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis Journal article
Li, Yue Kang, Ge, Fu Jing, Liu, Xiang Ning, Zeng, Chen Ming, Qian, Mei Jia, Li, Yong Hao, Zheng, Ming Ming, Qu, Jing Jing, Fang, Liang Jie, Lu, Jin Jian, Yang, Bo, He, Qiao Jun, Zhou, Jian Ya, Zhu, Hong. Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis[J]. Acta Pharmacologica Sinica, 2024.
Authors:  Li, Yue Kang;  Ge, Fu Jing;  Liu, Xiang Ning;  Zeng, Chen Ming;  Qian, Mei Jia; et al.
Favorite | TC[WOS]:0 TC[Scopus]:1  IF:6.9/7.6 | Submit date：2024/12/26
Acquired Resistance  Cftr  Ivacaftor  Nsclc  Osimertinib  
Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products Journal article
Zhang, Le Le, Zhang, Du Juan, Shi, Jia Xin, Huang, Mu Yang, Yu, Jia Mei, Chen, Xu Jia, Wei, Xiao, Zou, Liang, Lu, Jin Jian. Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products[J]. Phytomedicine, 2024, 132, 155828.
Authors:  Zhang, Le Le;  Zhang, Du Juan;  Shi, Jia Xin;  Huang, Mu Yang;  Yu, Jia Mei; et al.
Favorite | TC[WOS]:2 TC[Scopus]:3  IF:6.7/6.2 | Submit date：2024/07/04
Immunogenic Cell Death  Regulated Cell Death  Natural Products  Cancer Therapy  Tumor Immune Microenvironment  
Voluntary forward-looking disclosures and default risk pricing Journal article
Chen, C., Wei, M.H., Zhang, H., Yan, J.J.. Voluntary forward-looking disclosures and default risk pricing[J]. Accounting and Business Research, 2024.
Authors:  Chen, C.;  Wei, M.H.;  Zhang, H.;  Yan, J.J.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:2.0/2.8 | Submit date：2023/12/17
Management Forecast Reports  Multi-modal Information  Default Risk Pricing  Credit Default Swap  
Upregulation of Nrf2 signaling: A key molecular mechanism of Baicalin's neuroprotective action against diabetes-induced cognitive impairment Journal article
Zheng, Yanfang, Wang, Chenxiang, Liu, Wenjing, Chen, Jiaying, Sun, Yibin, Chang, Dennis, Wang, Huan, Xu, Wen, Lu, Jin Jian, Zhou, Xian, Huang, Mingqing. Upregulation of Nrf2 signaling: A key molecular mechanism of Baicalin's neuroprotective action against diabetes-induced cognitive impairment[J]. Biomedicine and Pharmacotherapy, 2024, 174, 116579.
Authors:  Zheng, Yanfang;  Wang, Chenxiang;  Liu, Wenjing;  Chen, Jiaying;  Sun, Yibin; et al.
Favorite | TC[WOS]:3 TC[Scopus]:4  IF:6.9/6.8 | Submit date：2024/05/16
Baicalin  Diabetes-associated Cognitive Deficits  Keap1-nrf2  Neuroinflammation  Nlrp3 Inflammasome  Oxidative Stress  
The role of major customers' qualitative forward-looking information in affecting suppliers' future operating performance (Conditionally Accepted) Journal article
Chen, C., Yuen, C.Y., Zhang, H., Yan, J.J.. The role of major customers' qualitative forward-looking information in affecting suppliers' future operating performance (Conditionally Accepted)[J]. Accounting Forum, 2023.
Authors:  Chen, C.;  Yuen, C.Y.;  Zhang, H.;  Yan, J.J.
Favorite |   IF:2.8/4.0 | Submit date：2023/12/17
Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer Journal article
Wang, Xianzhe, Shi, Wei, Wang, Xumei, Lu, Jin Jian, He, Ping, Zhang, Hongjie, Chen, Xiuping. Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer[J]. Cell Death Discovery, 2023, 9(1), 355.
Authors:  Wang, Xianzhe;  Shi, Wei;  Wang, Xumei;  Lu, Jin Jian;  He, Ping; et al.
Favorite | TC[WOS]:6 TC[Scopus]:6  IF:6.1/6.0 | Submit date：2024/01/02
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia Journal article
Mo, Jianshan, Deng, Lin, Peng, Keren, Ouyang, Shumin, Ding, Wen, Lou, Linlin, Lin, Ziyou, Zhu, Jianzheng, Li, Jingwei, Zhang, Qiyi, Wang, Pengyan, Wen, Yuanzhen, Chen, Xiaobing, Yue, Peibin, Lu, Jin Jian, Zhu, Kai, Zheng, Yongjiang, Wang, Yuanxiang, Zhang, Xiaolei. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia[J]. Journal of Hematology & Oncology, 2023, 16(1), 15.
Authors:  Mo, Jianshan;  Deng, Lin;  Peng, Keren;  Ouyang, Shumin;  Ding, Wen; et al.
Favorite | TC[WOS]:20 TC[Scopus]:19  IF:29.5/26.9 | Submit date：2023/03/06
Aml  Immunotherapy  Stat3 Inhibitor  Vista  
Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10 Journal article
Huang, Mu Yang, Chen, Yu Chi, Lyu, Wen Yu, He, Xin Yu, Ye, Zi Han, Huang, Can Yu, He, Xin Ling, Chen, Xiuping, Chen, Xiaobing, Zhang, Baoxian, Kai, Guoyin, Zhang, Xiaolei, Li, Ting, Huang, Mingqing, Lu, Jin Jian. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10[J]. Pharmacological Research, 2023, 198, 106988.
Authors:  Huang, Mu Yang;  Chen, Yu Chi;  Lyu, Wen Yu;  He, Xin Yu;  Ye, Zi Han; et al.
Favorite | TC[WOS]:14 TC[Scopus]:20  IF:9.1/9.0 | Submit date：2024/01/02
Combination Treatment  Ginsenoside Rh2  Pd-1/pd-l1  t Cells  Tumor Microenvironment  
Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis Journal article
Yu,Jie, Zhong,Bingling, Zhao,Lin, Hou,Ying, Ai,Nana, Lu,Jin Jian, Ge,Wei, Chen,Xiuping. Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis[J]. Drug Resistance Updates, 2023, 70, 100977.
Authors:  Yu,Jie;  Zhong,Bingling;  Zhao,Lin;  Hou,Ying;  Ai,Nana; et al.
Favorite | TC[WOS]:37 TC[Scopus]:37  IF:15.8/18.1 | Submit date：2023/08/03
Drug-resistance  Ferroptosis  Lung Cancer  Mam  Nqo1  
Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives Review article
2023
Authors:  Ye, Zi Han;  Yu, Wei Bang;  Huang, Mu Yang;  Chen, Jun;  Lu, Jin Jian
Favorite | TC[WOS]:14 TC[Scopus]:17  IF:14.7/14.1 | Submit date：2023/05/02
Bispecific Antibodies  Cancer  Cd47  Clinical Data  Combination Strategies  Future Perspectives  Mechanisms  Preclinical Data